Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma A Multicenter, Real-World Clinical Study
Latest Information Update: 28 Jan 2025
Price :
$35 *
At a glance
- Drugs Ensartinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 28 Jan 2025 New trial record